AFL · Q3 2025 Earnings

Narrative arc: Q2 stabilization candidate → Q3 active multi-product offensive.

Three quarters ago Japan was framed as a structural decline to be managed; last quarter as an inflection candidate with Miraito as the single proof point; this quarter as a coordinated three-product launch with a restructured organization purpose-built to execute it. Koide was explicit: "We changed the organization to be more cross-functional... The purpose of having this transformation is to launch the three brands or three products concurrently." Medical insurance launches end of December alongside Miraito and Sumitasa. This is no longer a recovery thesis — it's a platform reset, and the bar management has set for itself is materially higher than what Q2 framing implied.

US growth posture has shifted from "deliberate underweighting by design" to "exceeding our own trajectory." Q2 framed +2.7% sales growth as filtered-by-choice with 4Q enrollment as the test; this quarter Virgil said "We are actually exceeding the trajectory that we have put forth. So very pleased with that" on LAD specifically, with large-case growth running ahead of plan and the 4Q pipeline characterized as strong. The 4Q test from last quarter is being answered, in advance, with confidence.

Management is now explicitly cautioning against extrapolating Japan FSA earnings. Last quarter elevated Japan FSA earnings were treated as a tailwind to enjoy; this quarter Max walked it back: "If you have a yen strengthening, you could have the opposite. So I do want to caution you that this goes both ways." The implicit core annual run-rate is ~¥200B — a number that lets the sell side discount the FX overlay. This is unusually direct expectations management for Aflac.

The shift to ratio-based segment guidance is itself the most consequential disclosure change in years. By committing publicly to Japan pre-tax margin of 35–38% and US pre-tax margin at the upper end of 17–20%, management has given the market both a scorecard and a yardstick — and constrained their own ability to manage to softer outcomes without explanation. Combined with Max's statement that "a greater proportion of our imports are now gradually sitting in higher benefit ratio product categories... when you look at the total U.S. benefit ratio, that will structurally move up over time," the framework also pre-emptively explains why the US ratio will drift higher: it's mix, not deterioration.

M&A posture hardened from "open and patient" to "we don't have to do anything." Max: "I don't think that our views have changed on M&A... we don't have to do anything." Virgil: "we have not seen anything to come available that has attracted us." The implication: capital that was theoretically available for inorganic moves is now even more clearly earmarked for buybacks and dividends. The record $1B Q3 buyback is the proof.